Medicilon Logo
search icon search icon language icon contact icon menu icon
Medicilon Logo
search icon close search icon language icon contact icon menu icon
Contact Us
Close Button
Back To Top
Online Message×
Click switch
Close Button
Medicilon's News information
News information

New Approach to Better Therapy-Resistant Prostate Cancer

Page View:

Prostate cancer, also known as carcinoma of the prostate, is the development of cancer in the prostate, a gland in the male reproductive system. Most prostate cancers are slow growing; however, some grow relatively quickly. According to the American Cancer Society, prostate cancer is a second-leading means of genocide after lung cancer in American men.

Medicilon boasts nearly 300 tumor evaluation models. At the same time, we are empowering innovative therapies to comprehensively evaluate and study immuno-oncology. We have completed model establishment and efficacy evaluation of immuno-therapies such as CAR-T, TCR-T, CAR-NK, oncolytic virus, antibody (monoclonal antibody, double antibody, polyclonal antibody, etc.), siRNA, AAV.


    Prostate Cancer.webp


    A research team led by scientists at The Scripps Research Institute (TSRI) Florida campus has identified a novel approach to treating prostate cancer that involves blocking a newly discovered, constitutively active signaling circuit that plays a role in the development of androgen therapy resistance and aggressive tumor growth. Studies by TSRI associate professor Jun-Li Luo, Ph.D., M.D., and colleagues have found that inhibiting components in this circuit can hold back the progression of therapy-resistant advanced prostate cancer.


   Androgen therapy is the most effective treatment for advanced prostate cancer, but nearly all patients will eventually develop resistance. The signaling circuit identified by Dr. Luo and colleagues comprises the protein complex IκBα/NF-κB (p65), miR-196b-3p, Meis2, and PPP3CC and controls the expression of stem cell transcription factors that drive tumorigenicity. Being constitutively active, the circuit “is not dependent on the activation of other traditional IKKβ/NF-κB pathways that are important in normal immune responses,” the authors write in their paper “A Constitutive Intrinsic Inflammatory Signaling Circuit Composed of miR-196b, Meis2, PPP3CC, and p65 Drives Prostate Cancer Castration Resistance,” published in Molecular Cell. This “opens the door for potential treatment options,” Dr. Luo comments.

Related Articles:

Study Links Normal Stem Cells To Aggressive Prostate Cancer

New DNA Test May Predict Prostate Cancer Risk

Some Prostate Cancer Reflects Epigenetic Shift that Exposes Druggable Vulnerability

     NF-κB is a crucial target for cancer therapy. Still, NF-κB inhibitors can also cause severe side effects related to immunosuppression that results from the unwanted inhibition of NF-κB in normal immune cells. The TSRI research indicates that targeting the non-IκBα/NF-κB components in the newly discovered signaling circuit would avoid the suppression of NF-κB in normal immune system cells without affecting anticancer potency.


“Disrupting this circuit by targeting any of its components blocks the expression of these transcription factors and significantly impairs therapy-resistant prostate cancer,” suggests TSRI research associate Ji-Hak Jeong, the study's first author. “Our studies present deep insight into the bona fide mechanisms underlying castration resistance and provide the foundation for developing CRPC [castration-resistance prostate cancer] therapeutic strategies that would be highly efficient while avoiding indiscriminate IKK/NF-κB inhibition in normal cells,” the authors conclude.

Relevant newsRelevant news